Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf Nomination Swimming Upstream With Multiple Holds Now Possible

This article was originally published in The Pink Sheet Daily

Executive Summary

Two Senators could place holds on Robert Califf's nomination for FDA commissioner as HELP Committee sends it to the floor.

You may also be interested in...



Gottlieb Advances, But FDA's Future Seems Increasingly Partisan

Senate committee votes to send the FDA Commissioner nominee to the Senate floor, but with only two Democratic votes.

Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories

In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079005

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel